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ELSEVIER

Plasmodium falciparum
circumsporozoite vaccine
immunogenicity and efficacy trial with
natural challenge quantitation in an
area of endemic human malaria of
Kenya
J.A. Sherwood*t$-/-tj-,
R.S. Copelandj$
K.A. Taylor*l,
K. Abokll,
A.J. Olo~ll, J.B.O. Were*, G.T. Strickland**,
D.M. Gordon??,
W.R. Balloutt,
J.D. Bales Jr$, R.A. Wirtz$$, J. Wittes@, M. Gross@,
J.U. Quefl, S.J. CryaT, C.N. Osterllll, C.R. Roberts$ and
J.C. SadoF**
It has been hypothesized that antibody induced by Plasmodium
falciparum
circumsporozoite protein vaccine would be eflective against endemic human malaria. In
a malaria endemic region of Kenya, 76 volunteers, in 38 pairs sleeping adjacently, were
immunized with subunit circumsporozoite protein Asn-Ala-Asn-Pro tetrapeptide repeatpseudomonas toxin A, or hepatitis B vaccine. After quinine and doxcycycline, volunteers
were followed for illness daily, parasitemia weekly, antibody, T-lymphocyte responses,
and treated tf indicated. Anopheles mosquitoes resting in houses were collected, and
tested for P. falciparum antigen, or dissected for sporozoites and tested for blood meal
ABO type and P. falciparum antigen. Vaccine was safe, with side-eflects similar in both
groups, and immunogenic, engendering IgG antibody as high as 600 pug ml-‘, but did
not increase the proportion of volunteers with T-lymphocyte responses. Estimation of P.
falciparum challenge averaged 0.194 potentially infective Anopheles biteslvolunteerl
day. Mosquito blood meals showed no d@erence in biting intensity between vaccine and
control groups. Both groups had similar malaria-free survival curves, cumulative positive
blood slides, cumulative parasites mm - 3, and numbers of parasites mm - 3 on first
positive blood slide, during three post-vaccination observation periods. Every volunteer
had P. falciparum parastiemia at least once. Vaccinees had 82% and controls 89oY
incidences of symptomatic parasitemia (PzO.514, eficacy 9%, statistical power 95%
probability of eficacy ~50%). Vaccine-induced anti-sporozoite antibody was not
protective in this study. Within designed statistical precisions the present study is in
agreement with ejlicacy studies in Colombia, Venezuela and Tanzania.
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Natural antibody to sporozoite antigen increasing with
transmission intensity and age has been interpreted as
supporting the hypothesis that vaccine induced antibody
would protect against P. falciparum malaria’.2. Following demonstration that humans could be protected from
sporozoite challenge by subunit sporozoite vaccines
((Asn-Ala-Asn-Pro), 5 Asn-Val-Asp-Pro),=R32,
with
relatively low levels of antibodies against the central
repeat region of P. falciparum circumsporozoite protein3’4 second generation vaccines were designed to elicit
higher levels of antibody. It may be hypothesized that
supra-normal levels of antibodies to sporozoites could
protect, even though natural levels are not correlated
with the prevalence of parasitemia or time to onset
of parasitemia5. Increased T-lymphocyte responses to
sporozoite epitopes may protect, since circurnsporozoite
protein repeat has a T-lymphocyte
epitope’j, and
endemic adults have T-lymphocyte responses to an
epitope of the circumsporozoite protein repeat7. Efficacy
in an endemic population with circumsporozoite repeat
(Asn-Ala-Asn-Pro),-tetanus
toxoid is unclear’.
Immunogenicity
and small-scale efficacy trials in
malaria naive volunteers identified R32-Toxin A vaccine
as suitable for further evaluation’. This vaccine produced high sporozoite antibody levels in non-immune
volunteers, was safe, and immunogenic, nearly all
vaccinees seroconverting”. One of eight volunteers was
protected from challenge with laboratory
infected
mosquitoes, even though titers fell to relatively low
levels at the time of challenge.
This endemic field trial was performed because of
higher and more sustained antibody levels in response to
vaccination with circumsporozoite repeat in a malaria
endemic” than in naive3 volunteers and because wild
mosquitoes have’* and release13 fewer sporozoites than
laboratoryi
mosquitoes.
MATERIALS AND METHODS
Study site

The study area, in western Kenya, near Lake Victoria,
has been a site of community-based medical research
studies’ 5 and has been described15-17. The incidence of
P. falciparum alone or with P. malariae or P. ovale was
98.1% between 1980 and 1983”.
Study design

This was a prospective, placebo-controlled, randomized, paired, double-blinded, active-case-seeking study.
P. falciparum malaria incidence has been 90%5, and 89%
over 4 months7, therefore a vaccine 50% effective would
give an incidence of 45% in the experimental group. In
this instance, the number of volunteers needed in each
group for significance of 0.05 and power of 0.95 in a
2-tailed test is 29 19. In previous studies in this area the
drop-out rate was 15% over 8 months5s7, 1.87% per
month or 22.5% per 12 months.
Recruitment, pairing, randomization,
clearance, treatment and follow-up

anti-malarial

From a censusi7, of five villages near a clinic, an
update was made of males between the ages of 18 and
30 years. One hundred and twenty-seven prospective
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volunteers answered a questionnaire; 110 met criteria;
76 volunteers were enrolled. Volunteers and household
family members were offered free medical care during
the study and for any potential adverse effect of vaccine
or medicines. Inclusion criteria: male, age 18-30 years,
in good health, willing to reside in the study area
and participate for 12 months, use no bed nets or
other malaria prophylaxis during the study, and
human immunodeficiency virus-l (HIV) antibody test
negative2’. Exclusion criteria: evidence of cardiac,
pulmonary, renal or immunologic disease, or antibody
to HIV.
Volunteers were asked to pair themselves to sleep in
the same house. Paired volunteers were assigned to two
groups of similar ages and proportions of hemoglobin
AS. Vaccine was randomly assigned. Houses were
inspected to ascertain that they were the customary
sleeping houses of the community. Reed mats provided
uniform ceilings for mosquito resting and collection.
Interiors were divided by a wall or curtain into separate
sleeping areas. Every 7 days volunteers switched bed
positions in houses.
Volunteers were given quinine sulfate 650 mg thrice
daily for 3 days and doxcycycline 100 mg twice daily for
7 days, before each of the three vaccinations. After the
last vaccination, volunteers were given quinine sulfate
650 mg thrice daily for 3 days and doxycycline twice
daily for 28 days to eradicate blood stage and hepatic
stage parasites. Clinical workers observed swallowing of
medicines. For slide-proven
malaria, sulfadoxinepyrimethamine (Fansidar) was prescribed and swallowed in the presence of clinic staff. Chloroquine and
amodiaquine were not prescribed. Volunteers were
advised to avoid chloroquine and amodioquine, available without prescription, and obtain medicines only
from the study clinic.
Follow-up was carried out for 12 months, 6 months
after the last vaccination. Each morning, a clinical
worker asked if the volunteer felt sick, took the axillary
temperature and asked of any medicine taken. Symptoms of malaria were considered to be: fever; chills;
sweats; headache; cough; or diarrhea. If the volunteer
felt ill with a symptom of malaria, then a blood slide was
made. If the volunteer was moderately ill or worse, he
was taken to the clinic by the clinical worker for history
and physical examination and tests including malaria
blood slide read in the clinic. Symptomatic malaria was
defined as the presence of one or more of the above
symptoms plus a blood slide positive for P. falciparum.
Volunteers were given treatment for malaria if they had
both a symptom consistent with malaria and a positive
blood slide. After each vaccination, volunteers wrote
down side-effects.
Vaccine

The experimental vaccine was recombinant (Asn-Ala(R32LR)*“**
Asn-Pro, 5 Asn-Val-Asp-Pro),-Leu-Arg
covalently linked to purified Pseudomonas aeruginosa
toxin A 9. Each dose consisted of R32LR peptide
(175 pug), and toxin A (225 pg)” or recombinant
hepatitis B vaccine (Energix B, SmithKline Beecham)
control. Malaria (Swiss Serum and Vaccine Institute)
and hepatitis vaccines were sent separately to Kenya.
Vaccines were kept and transported at +4”C, in the dark,
until use.
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immediately before the third vaccination, and 1 month,
2 months and 6 months after the third vaccination7.

Entomological

Day
Figure 1 Study intervals. The expected
clearance, or prophylaxis, is 14 days

prepatent

Clinical parasitology,
chemistry

hematology

pharmacology,

period

after

and

Scheduled blood slides, in duplicate, were made every
7 days23 from 2 weeks before until 52 weeks after the
first vaccination and the number of parasites mm ~ 3 was
determined. Symptomatic blood slides were examined at
the clinic24. For a slide to be considered positive, at least
five asexual stage parasites had to be seen. These slides
were later confirmed by others in a laboratory and
results returned to the clinic. If a slide was read as
negative in the clinic and later found to be positive, the
volunteer was treated. There were no slides read as
positive in the clinic that were negative on confirmation.
Unless otherwise stated, parasitemia refers only to P.
falciparum, and not P. malariae or P. ovale. The tabulation of blood slides for the purpose of vaccine efficacy
was begun 14 days after the day of completion of
doxycycline administration (not with the day after the
completion of immunization), to avoid including any
recrudescent parasites. Thus, observation periods 1 and
2 began 14 days after each of the first two vaccines were
given (Figure 1 and Figure 4a,b), and observation period
3 began 60 days after the third vaccine was given (study
day 230, Figure 1 and Figure 4~).
Serum doxycycline was assayed by reverse phase
high-pressure liquid chromatography
on samples from
the 9th, 10th or 1 lth day of prophylaxis . Urine
was collected every 4 weeks, frozen and analyzed for
aminoquinolines26, 7.
Clinical hematology, urinalysis and chemistry tests
were performed at initial screening, monthly for 12
months and when clinically indicated.
Humoral and cellular immunology

Levels of anti-P. falciparum circumsporozoite
(CS)
antibody were determined by enzyme-linked immunosorbent assay (ELISA)28 with capture antigen R32LR.
Standard sera containing 9.8 pugof IgG antibody per ml,
specific to R32 from a previously vaccinated volunteer3,29 and test sera, gave co-parallel curves of absorbance vs concentration when tested against R32LR3’.
Positive was defined as the mean plus 3 S.D. of nonimmune sera without exposure to malaria. Rise in titer
was defined as a level 3 S.D. above the preimmunization level for that individual. Immunofluorescent assay for antibody to sporozoites was performed
before the first and after the third vaccination’ ‘.
Lymphocyte proliferation was performed 4-8 days
before the first vaccination,
1 month before and

background and measurement

The Anopheles abundance of the study area has been
described3 -33. Over 33 months, An. gambiae sensu latu
and An. funestus comprised 90% and IO%, respectively,
of human-biting Anopheles, and mean daily man-biting
rates for An. gambiae s.1. and An. jiinestus were 3.3 and
0.6, respectively32. In this area, sporozoite rates by
salivary gland dissection were 6.2% 4-13.10h32 for An.
gambiae, and 4.9%32 for An. funestus. Sporozoite rates
by ELISA of undissected head and thorax samples were
15.1% and 14.2%, respectively, for An. gambiae s.1. and
for An. funestus35, and, in a nearby site 8.2% and 6.1%
for these species33. The threshold of ELISA sensitivity
is about 125 sporozoites per mosquito36. Sporozoite
burdens in East Africa for An. gambiae and An. funestus,
were reported to be 20004000 per salivary gland37. In
western Kenya A. gambiae had a Beometric mean of 962
and A. funestus 874 sporozoites 2. In western Kenya,
86.6% of naturally infected An. gambiae transmitted,
into sucrose or blood, a geometric mean of 3.84 sporozoites (range l-34), about 3% of the total sporozoites in
salivary glands13. In contrast, laboratory reared An.
gambiae contained 808-13905 sporozoites, and 44.1% of
infected laboratory An. gambiae transmitted a geometric
mean of 4.5 (maximum 369) sporozoites in vitro, with
which sporozoite loads were not a predictor of the
number of sporozoites ejected14. The entomological
inoculation rate (EIR), calculated as the monthly man
biting rate times the sporozoite rate”‘, or the average
number of potentially infective Anopheles bites in a
period of time, was during a previous study in Saradidi,
237 per year inside houses, and 190 per year outside
houses32. The calculated time to inoculation exposure,
to experience one potentially infective bite, is l/EIR, for
Saradidi, inside houses, 1.5 nights32.
Six mornings per week, a 0.5 h collection of indoor
resting mosquitoes was made by volunteers in the
houses. One morning per week, experienced entomology
workers made the collections.
Mosquitoes
were
identified to species, and examined for the presence of
blood. Four days per week, Anopheles were killed,
desiccated and mosquito thoraces were tested later
for P. falciparum antigen, by ELISA3’. Three days
per week, mos3guitoes salivary glands were dissected
for sporozoites , which were tested by ELISA for P.
falciparum antigen3’ and mosquito blood meals were
typed for blood groups A, B and 04’. Group 0 blood
cells were detected by agglutination in the presence of
lectin H (American Dade, Miami, FL). Mosquitoes were
determined to have fed on a volunteer when the blood
type of the blood meal was the same as the blood type of
the volunteer, in those pairs of volunteers with differing
blood types. Blood meal host origin was determined
by ELISA for human or cow immunoglobulin4’. In
a previous study, of A. gambiae s.1. and A. funestus
collected in houses in Saradidi, 100% of blood meals
were human or cow 4’ . At the conclusion of the observation period (16 May 1991) 119 pyrethrum-spray-catch
collections39 were made in volunteer’s houses, immediately following collections by volunteers. These supplemental collections were done to derive an estimate of the
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Table 1 Age and erythrocyte characteristics
immunogenicity and efficacy trial

et

al.

of vaccine and control volunteer

groups in a

Study groups

irAzean

(SE.)”

PkSmodkm~

fakiparum

circumsporozoite

Vaccine

African groups

Vaccine

Control

Total

(No.)

(No.)

(No.)

20.6
38
30

0.53
79%
100%

z.2
30

0.45
79%
100%

76
60

79%
100%

Kenyans”

American?

28% (Foy, 1982)
26% (Allison, 1954)

8% (Bunn, 1991)

HbAS’
HbAS
A’.
AEJ’

5

13%

6

16%

11

14%

13
3

34%
8%

6
4

16%
11%

19
7

25%
9%

39% (Giblett, 1991)
4% (Giblett, 1991)

;..
Rh(D) Pos.
Rh(D) Neg.
GGPDNormal”’
GGPDDeficient”’

715
38
0
35
3

39%
18%
100%
0%
92%
8%

18
10
37
0
33
5

26%
47%
97%
0%
87%
13%

33
17
75
0
68
8

22%
43%
99%
0%
89%
11%

50%
17% (Giblett, 1991)
95+% [Giblett, 1991)
72% (Allison, 1960)
28% (Allison, 1960)

‘,+0.077,
kO.7816,
d.f. =I. “x2=3.524, EO.3188, d.f.=3.
***x2=0.559,
fk0.4547, d.f.=l_ Probability distribution 2=0.31577, 60.40. Wifcoxon’s
rankino/Mann-Whitnev,
z=-0.603,
-0.7257.
“Luo people of same study area of Kenya. bAmericans of African descent. ‘(Mean Of VaCCitle
group-1
S.E.)s(mean of control group +l SE.)

percentage of total indoor resting mosquitoes
that were
obtained
on
average
during
morning
aspiration
collections
by volunteers.
No vector control methods
were exercised in the area during the present vaccine
study.
Statistical analysis
Efficacy was calculated
using the formula
I=1 (1,/1,), where &incidence
of symptomatic
parasitemia,
I,=incidence
in the vaccine group, and IrEincidence
in
the control group. Analysis of variation, x2, correlation
coefficient, Fisher’s exact test, Kaplan-Meier
survival
curve with log-rank test, and Student’s t-test were used.
Statistical calculations
were determined
with the assistance of StatView 5 12+ TM (Brainpower,
Inc., Calabasas,
California,
1986).

RESULTS
Study population and follow up
Age means were similar for the vaccine and control
groups (Table I). The distribution
of sickle trait was
similar between the study population
and the general
and between the vaccine and control
population4244
groups. There was no significant difference between the
study population
and a previously reported distribution
of ABO blood types in this population
of western
Kenya4’. There was no significant
difference between
vaccine and control
groups in distribution
of ABO
blood types. The prevalence
of glucose-6-phosphatase
dehydrogenase
deficiency
was similar
between
the
study population
and the general population46.
There
was no significant
difference
between
vaccine
and
control groups in prevalence of glucose-6-phosphatase
dehydrogenase
deficiency (Table 1).
There was no significant difference in volunteer participation
between
the vaccine
and control
groups
(P>O.25, log rank test). Sixty-nine
of 76 volunteers
completed the study on day 367. All who left did so for
personal
reasons: to further their education
or seek
employment
away from the study area.
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Safety and adverse reactions
There were no serious adverse reactions
to the
vaccines or medicines.
Adverse reactions
to vaccines
were few in number,
mild in intensity,
and brief in
duration in both vaccine and control groups. There were
no adverse reactions manifest by the clinical hematology
or chemistry tests.

Humoral and cellular immunology
Among those receiving hepatitis vaccine control, 4 of
38 volunteers
(10%) had an antibody rise to R32LR 3
S.D. above the arithmetic mean. Among those receiving
malaria vaccine, 73% (28 of 38) had an antibody rise to
R32 3 S.D. above pre-immunization.
The geometric
mean titers for the malaria group increased after each of
the vaccinations
and fell during the interim (Table 2,
Figure 2). The geometric mean titers for the control
group did not change (Figure 2).
Among those receiving malaria vaccine there were
three patterns
of antibody
response: no increase, an
increase with a drop toward baseline, and a sustained
increase.
Those
not
responding
had
lower
prevaccination
levels, and those responding
had higher
pre-vaccination
levels, in agreement with the previous
vaccine study showing greater response in those with
higher natural levels”. In most, the third vaccination did
not increase antibody levels beyond that achieved by the
first or second vaccinations.
The highest antibody level
achieved was 600 pg ml- ’ . Four of 38 volunteers (10%)
receiving malaria vaccine had peak levels in this range.
Among
controls,
some had low levels of antibody,
unchanged during the course of the study, and some had
higher levels, also unchanged.
There was an association
between increase in sporozoite
immunofluorescence
score
with
increase
in
antibody
by ELISA
(n=14)
and no increase
in
immunofluorescence
with no increase in antibody
by
ELISA (n=9), among those receiving malaria vaccine
(n=33) (Pl+P2=0.002,
Fisher’s exact test), indicating
peptide vaccine increased antibody
to natural sporozoites, although
a subset (~10)
had no increase in

Malaria vaccine trial: J.A. Sherwood et al.
Table 2

Anti-circumsporozoite

antibody

levels of vaccine and control volunteer

Vaccine

groups in a Pktsmodium falciparum malaria vaccine trial
Control

Time (weeks)

Mean”
(mcg ml-‘)

Minimum
(mcg ml-‘)

Maximum
(mcg ml-‘)

1 SD.
(mcg ml-‘)

Mean=
(mcg ml-‘)

Minimum
(mcg ml-‘)

Maximum
(mcg ml-‘)

1 S.D.
(mcg ml-‘)

0.0
4.0
8.0
12.0
16.0
20.0
24.0
28.0
34.0
40.0
44.0
48.0
52.0

5.3
63.4
52.5
135.6
41.8
42.7
37.1
50.8
43.2
27.1
23.4
31.1
23.7

0.3
3.3
4.6
7.2
3.0
3.5
4.7
2.0
4.6
4.2
2.8
3.2
3.8

23.0
66.2
500.0
3200.0
298.2
327.0
373.1
285.4
273.3
167.4
170.9
217.9
190.1

4.4
129.0
94.2
521.2
65.4
61.2
66.3
58.0
62.6
31.9
31.8
50.5
34.5

6.9
9.5
12.8
11.3
9.0
11.3
9.0
8.1
8.3
10.0
6.7
7.2
8.2

0.4
0.4
1.2
0.7
0.6
0.4
0.3
:::

73.9
45.8
117.1
75.4
72.3
75.5
55.8
47.8
29.2
50.4
27.7
29.0
31.3

12.5
10.5
22.1
14.3
12.8
14.9
11.8
9.8
7.8
11.5
7.3
7.3
8.0

“Geometric

0.4
0.4
0.6
0.7

mean

0

1.2,

-4

0

4

8

12

16

20

24

Time

28

32

36

40

44

48

52

56

60

(Weeks)

Figure 2 Geometric mean antibody levels for vaccine and control
groups. At week 0 there was no significant difference between
vaccine and control groups in antibody levels (E0.417,
analysis
of variance). From 4 to 52 weeks there were significant differences between vaccine and control groups in antibody levels
(EO.OOl -0.021,
analysis of variance)

immunofluoresence
with an increase in antibody by
ELISA.
Lymphocyte responses to R32LR were determined in
the 11th or 12th month of the study, using fresh,
non-cryopreserved, lymphocytes. Results were available
on 52 of 76 volunteers (68%), four of whom had positive
responses. Two were from the control group, and two
from the vaccine group. Among these four volunteers,
there was no association between lymphocyte response
and post vaccination antibody level. Among all volunteers, there was no association between lymphocyte
response and mean change in antibody level after each
of the three vaccinations
(P=O.964, 0.820. 0.870,
ANOVA). The malaria vaccine group did not have an
increase in the proportion of volunteers responding to
the antigen as a T-lymphocyte epitope, in comparison
with the placebo group. There was no correlation
between age and stimulation index at end of study
(r= - 0.055, n=52). T-lymphocyte responses to R32LR
were assayed in the 1 week before the first vaccination,
using fresh lymphocytes. Technical difficulty prevented
completion of the pre-vaccination assay.
Entomology

and parasitologic challenge

From May 1990 to May 1991, 10.9% of 18138 desiccated Anopheles females were positive for P. falciparum
antigen by ELISA. Of these, A. gambiae comprised
66.5%, A. funestus 32.1% and A. arabiensis 1.4%. 7.75%

House

number

Figure 3 Infected Anopheles per day per house. Average of I?
falciparum antigen positives by enzyme-linked
immunosorbent
assay of dried thoraces

of 7842 Anopheles females were P. falciparum sporozoite positive, by ELISA, after salivary gland dissections. Therefore, 71.1% of ELISA-positive desiccated
Anopheles were potentially
infective (i.e. had P.
falciparum sporozoites in salivary glands). Plasmodial
circumsporozoite
antigen exists in anophelene gut,
thorax, and salivary glands during the structural development of the incipient sporozoite, before and possibly
after, the sporozoite is functionally infective. The presence of antigen alone, in thorax or in salivary gland, by
ELISA, does not equate to infectivity. Furthermore, if
~125 sporozoites per mosquito are present, the ELISA
may be negative, being below the ELISA test threshold.
Visual dissection for the presence of sporozoites was
performed and this material tested for P. falciparum
circumsporozoite antigen by ELISA.
For desiccated mosquitoes, the total number of P.
falciparum ELISA-positive Anopheles caught was 1971.
The calculated average of infected Anopheles collected
per volunteer was 0.137 per day. The average number of
infected Anopheles captured per day among the study
houses ranged from 0.02 to 1.18 (Figure 3). The mean,
minimum and maximum number of infected Anopheles
per house per day varied for each of the three
observation periods (Table 3).
Of 18 138 mosquitoes 63.2% blood fed by visual
inspection. Of 4029 blood-fed mosquitoes for which
blood was typed, 94.3% matched the blood type of one
of the volunteers in the house in which the mosquito was
caught, suggesting that ingress of blood fed mosquitoes
from the outside was minimal. Twenty-eight of the 38
houses contained volunteers with different blood types.

Vaccine 1996 Volume 14 Number 8

821

Malaria vaccine trial: J.A. Sherwood et al.
Table 3 Number of Plasmodium
efficacy trial
Observation

perioda

falciparum

sporozoite-containing

mosquitos

per house per day in a malaria vaccine immunogenicity

Number of housesb

Mean

1 S.D.

Median

Minimum

Maximum

1

38

0.469

0.426

0.383

0.000

2.083

5

:;

0.241
0.090

0.272
0.126

0.127
0.041

0.000

0.640
1.315

=?=l Jun to 1 Jul; 2=27 Jul to 22 Ott; 3=31 Dee to 17 May. bn=Number of houses; some volunteers

Table 4

Symptomatic

malaria in vaccine and control groups in a Plasmodium
Number of volunteers

having symptomatic

Vaccine
Observation

period

n

1

38

:
1+2+3

34
38
38

“x2 with continuity

correction.

25
;3
31

malaria

of symptomatic

Control

malaria

n

No.

%

pa

No.

No.

P

24

38

11

29

0.795

11

12

0.384

74
61
a2

:;
38

22
30
34

86
59
a9

0.338
0.888
0.514

56
39
106

44
65
121

0.261
0.250
0.343

bPaired, l-tailed

f-test

pharmacology

Serum doxycycline levels ranged in the vaccine group
(n=34) from 0.196 to 2.975 pg ml- ’ (mean f 1 S.D.
=0.797 f 0.555 ,ug ml- ‘), and in the control group
(n=35) from
0.145 to 2.686 (mean& 1 S.D.=
0.795 f 0.606 ,ug ml- ‘), between expected published
peak (5 pugml - ‘) and trough (1 pugml - ‘) levels47. There
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Number of occurrences
Vaccine

%

There was a significant positive correlation between the
vaccine and control group pairs in numbers of blood fed
Anopheles containing blood of the same type as a
volunteer in a house (r2=0.50, P~O.001). There was no
difference between vaccine and control groups in the
number of blood meals from a sporozoite-positive
Anopheles associated with individual volunteers (paired
t-test, t=0.68, d.J=24, P=O.50).
Four parameters were used to estimate total malaria
challenge on volunteers. A=Proportion potentially infective of desiccated ELISA-positive
Anopheles=0.711.
B=Proportion
of blood fed Anopheles of the total
collection=0.632. C=Average number of infected desiccated Anopheles collected per volunteer per day throughout entire study=0.137. D=Number of times greater the
pyrethrum spray catch (PSC) collections were than the
accompanying
aspiration collections by volunteers
(ACV); on average=2.149. PSC collections and ACV
were significantly correlated (loglO(PSC+1)=0.52062 x
loglO(ACV+1)+0.74362; ?=0.351, P<O.OOl).
Estimate of total challenge=A x B x (C+(D x C))=
0.711 x 0.632 x (0.137+(2.149 x 0.137))=0.194
potentially infective bites per volunteer per day, or one
infective bite every 5.2 days.
There was no significant difference in the distribution
of P. falciparum sporozoite-infected
mosquitoes per
house among the blood types 0, A, B and AB for
vaccine (P=O.597) or control (PzO.565, ANOVA). There
was no significant difference in the distribution of P.
falciparum sporozoite-infected mosquitoes with matching blood type per volunteer among the blood types 0,
A, B and AB for vaccine (P=O.384) or control (P=O.381,
ANOVA).
Antimalarial

moved to new houses

falciparum malaria vaccine trial

Control
No.

and

Vaccine 1996 Volume 14 Number 8

were no positive blood slides during the 14 days following the last dose of doxycycline, the expected prepatent
period, had an infective bite been received on the first
day following cessation of doxycycline. Fifteen of 78
volunteers, each on only one occasion, had a positive
urine test for aminoquinoline, indicating compliance
(1.6% of a possible 912 occasions) in taking only those
medicines prescribed in the clinic, not chloroquine or
amodiaquine available commercially.
Clinical and parasitological

outcome

During the three postvaccination observation periods,
the number of volunteers who developed symptomatic
malaria in the vaccine group and control groups were
comparable, and there were no significant differences by
x2 analysis (Table 4). The number of occurrences of
symptomatic malaria during each of the three postvaccination observation periods in the vaccine and control groups were comparable, and there were no
significant differences by paired t-test (Table 4). Efficacy
was calculated according to the formula I=1 - (I,/
I,)=1 - (31/38)=0.09=9% . The mean number of fever
occurrences from any cause, defined as a temperature 3
S.D. above the mean, was 1.3 (range O-5, n=38) for the
vaccine group and 1.7 (range O-5, n=36) for the control
group. There was no significant difference between the
two groups of paired volunteers in the number of fever
occurrences (paired 2-tailed r-test, t= - 1.247, dj=35,
P=O.2208).
None of the volunteers died during the study. None of
the volunteers had severe malaria (defined as a positive
blood slide for malaria with seizure, loss of consciousness, or hypotension (blood pressure ~80 systolic),
cerebral malaria (defined as a positive blood slide with
sustained coma)), a seizure, loss of consciousness, or
change in mental status.
All volunteers had at least 1 positive blood slide for P.
falciparum during each of the three observation periods
after each of the three vaccinations, except 1 vaccine and
1 control in the first observation period (Figure da), both
of whom had positive slides at the next clinic visit for
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40
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time in days to first positive blood slide, cumulative
number of positive blood slides, or cumulative number
of parasites mm - 3 during the third observation period
from weeks 34 to 52. Correlation between mean antibody levels over weeks O-52 and number of days to first
positive blood slide was rE0.3.
There was no difference between volunteers with and
without T-lymphocyte responses in time to first positive
slide, total number of positive slides or cumulative
parasitemia.
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Figure 4 Kaplan-Meier
actuarial curves. The tabulation of blood
slides for the purpose of vaccine efficacy was begun 14 days after
the day of completion of doxycycline administration (not with the day
after the completion of immunization), to avoid including any recrudescent parasites. Thus, observation periods 1 and 2 began 14 days
after each of the first two vaccines were given (study days 14 and
70, see Fig. 1). Observation period 3 began 14+28=42 days after the
third vaccine was given (study day 230, see Fig. 1). (a) First
observation period. Log rank t=O.O3169, E-0.25, not significant. (b)
Second observation period. Log rank r’=O.5585, 60.25,
not significant. (c) Third observation period. Log rank r’=O.6629, 130.25, not
significant

the second vaccination. The highest P. falciparum parasitemia in any volunteer was 63054 mm - 3. Survival
curves for the proportion
of volunteers free of P.
falciparum on blood slide after the first, second and third
vaccinations showed no difference between the vaccine
and control groups by log rank test (Figure 4a-c). Blood
slide results for the two groups of paired volunteers in
the three observation periods are show in Table 5. There
was no significant difference in the mean number of days
until the first positive slide (patency), the total number
of positive slides, the cumulative number of P. falciparum mm - 3 (parasite densities), or mean number of P.
falciparum mm - 3 on first positive blood slide. Twentyeight (36.8%) of 76 volunteers had P. malariae alone or
mixed parasitemia for a total of 61 times. Twenty-two
(28.9%) of 76 volunteers had P. ovale alone or mixed
parasitemia for a total of 29 times. The prevalences of P.
falciparum, P. malariae and P. ovale are shown (Table 6).
There was no significant correlation between antibody
level at weeks 0, 8, 12, 16, 20, 24, 28, 34, 40, 44, 48 and
52, or the mean over weeks O-52 or 34-52, or the change
in antibody level from weeks O-4, 8-12 or 24-28, and

DISCUSSION
This field study was designed to determine the safety and
efficacy of a recombinant alum adjuvanted subunit
vaccine which induces antibodies against the repeat
region of the P. falciparum circumsporozoite protein, in
a malaria-experienced
population. This vaccine was
safe, with a rate of side-effects comparable to that of
recombinant hepatitis B vaccine.
The vaccine induced high levels of antibody in a
subpopulation,
higher than seen previously in nonimmune or in semi-immune volunteers. In this endemic
population, responders to this vaccine had higher preimmunization
natural
antibody
levels than nonresponders, as was observed in a similar population no
longer living in a malaria endemic area”. Antibody
levels of vaccines decreased gradually over 12 months.
There was an association between having an increase in
antibody by ELISA and immunofluoresence, indicating
reaction with native sporozoites, but there remained a
subset (10 volunteers) who had antibody by ELISA but
not by immunofluoresence.
In volunteers immunized
with (NANP)3-tetanus toxoid or recombinant R32tet32,
although there was a correlation between level of IgG in
protected human volunteers and inhibition of sporozoite
invasion of cultured HepG2A-16 hepatoma cells, IgG
from protected human volunteers did not block sporozoite invasion of human hepatocytes4’. Sporozoites can
develop into hepatic schizonts in the presence of antibody to R3249. High levels of antibodies reacting with
sporozoites by immunofluorescence inhibit entry and
development of sporozoites in hepatocyte culture by
only 82-88% and have been found in the presence of
blood stage P. falciparum infection, suggesting that a
single antigen vaccine may not be adequate5’. Mouse
antibody against the R32 recombinant peptide has a
delayed inhibitory effect on development of sporozoites
in liver cells49. Repeat epitopes may induce a distracting B-l phocyte production of non-protective antibody5’, y”
2. In the present study the level of antibody did
not correlate with the number of positive slides, time to
onset of parasitemia or total burden of parasites.
The vaccine did not increase the small proportion
mounting a T-lymphocyte response. The present result
is consistent with a report that NANP repeat is a
T-lymphocyte epitope on the circumsporozoite protein6,
but recognized by only a portion of the population (4
of 52=7.7%), in agreement with previous results from
the same area (2 of 28=7.1°h)7. The repeat region is
conserved among widely separated regions53. Such
conservation may reflect the low frequency of individuals whose T-lymphocytes recognize the repeat. Polymorphisms in T-lymphocyte epitopes lie outside the
repeat region 54s5. Although exposure to sporozoites
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Table 5

Time to first parasitemia, number of episodes of parasitemia, aggregate numbers of parasites, and parasite density in first episode of
parasitemia in vacccine and control volunteer groups in a Plasmodium falciparum malaria vaccine trial
Vaccine

Observation

period

Control

n

Min

Max

n

Mean

Min

Max

pa

14
15
26

4
2

25
69
a5

37
35

:;
23

4
4

73
25
71

0.198
0.366
0.252

No. positive blood slides for F! falciparum
1
38
2
2
38
5
3
34
7

0
0
1

4
12
la

38
37
35

2.2
5.4
6.4

0
1
1

4
13
14

0.452
0.399
0.139

No. P. falciparum
1
2
3

mrne3
0
0
58

22687
27918
36802

38
37
35

794
1471
6217

0
2
3

6118
13757
62049

0.169
0.496
0.214

No. P: falciparum

mm-3 on first positive blood slide
21
2

6405
4971
8080

z;
35

390
169.7
791

:
3

5659
1705
13015

0.183
0.249
0.332

Mean

No. days to first positive blood slide for F! falciparum
:
3

37
38
34

38
38
34

:
3

1470
1441
4350

37
36
34

297
155
582

BPaired, 1 -tailed f-test

Table 6 Prevalence
malaria vaccine trial

of Plasmodium

falciparum,

Plasmodium

malariae and Plasmodium

Vaccine

ova/e in vaccine and control volunteer

Control

groups in a

Combined

Species

n

%

n

%

n

%

F! falciparum
I? malariae
I? ova/e
I? falciparumi P malariae
F1 falciparum+P ova/e
F! malariae+P. ova/e
I? falciparum+P malariae+i?
Total any F! falciparum
Total

604
14
4
14
9
0
1
628
646

93.5
2.2
0.6
2.2
1.4
0.0
0.2
97.2
100.0

571
13
a
9
z

94.2
2.1
1.3
1.5
0.8
0.0
0.0
96.5
100.0

1175
27
12
23
14
0

93.8
2.2
1 .o
1.8
1.1
0.0
0.1
96.9
100.0

ova/e

boosts immunity initiated by a sporozoite vaccine in
mice56, exposure to natural sporozoites after the third
vaccination did not appear to increase the proportion of
volunteers with a T-lymphocyte response. P. berghei
sporozoites do not prime mouse T-lymphocytes for
circumsporozoite epitopes5’, which appears to be the
case for P. falciparum sporozoites in humans, based on
the 7% prevalence of T-lymphocyte response to R32LR
in this study.
This vaccine did not protect this population against
malaria. All volunteers acquired parasitemia. Vaccine
and control groups had the same malaria-free survival
curves, number of positive slides for malaria, parasite
densities. This vaccine had protected 1 of 8 non-immune
American vaccinees from sporozoite challenge, using 5
laboratory infected An. stephensi mosquitoes, at least
50% of mosquitoes infected with at least 2+(10-100
sporozoites per gland)“, with a correlation between
immunofluorescence
and antibody by ELISA”. With
this vaccine there had been no correlation between
serum inhibition of sporozoite invasion of hepatoma
cells with human protection”.
Close follow-up and
early treatment may have precluded the development of
severe malaria, so a vaccine effect on this could not be
determined.
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585
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:213
1252

This study provides an indirect comparison of experimentally infected laboratory mosquitoes with natural
field exposure. The entomological challenge in numbers
of P. falciparum
sporozoite-infected
mosquitoes per
volunteer was 0.194 per day, an average of one infectious bite every 5.2 days. Five laboratory infected
mosquitoes at once have been used in laboratory efficacy
studies3,4%‘0.It may be thought that the malaria challenge is high in western Kenya, and too severe a test
for vaccine efficacy. However, in this study, there was
a 70-fold range in challenge, 3.5-245 P. falciparum
infected mosquitoes collected per house. It was important to conclude that absence of malaria was not due to
absence of infected mosquitoes.
The SPf66 vaccine has the sequence CGDELEAETQ
NWAAP NANP YSLFQKEKMVLP NANP PANKK
NAG (NANP=Asn-Ala-Asn-Pro)58.
Immunization of
rabbits with SPf66 induced antibody to (Asn-Ala-AsnPro)40, but not of monkeys nor human volunteers5*.
SPf66 has been reported 33.6% effective (95% confidence interval l&845.7%), against a first episode of
endemic malaria, with blood slides made every 4-8
in
weeks, in a semi-immune human population
Colombia59, statistically in agreement with the present
study (for asymptomatic parasitemia efficacy was O%,

Malaria

for symptomatic parasitemia efficacy was 9%, statistical
power 95% probability of efficacy ~50%). Antibody
levels to Asn-Ala-Asn-Pro
did not correlate with
incidence59. It is not clear to what extent two
non-contiguous copies of (Asn-Ala-Asn-Pro) in SPf66
contributed to immunogenicity or efficacy. SPf66 was
reported to be 55% effective (95% conficence interval
21-75%) with blood slides made every 4-S weeks, in
Venezuela6’, also statistically consistent with the present
study (for asymptomatic parasitemia efficacy was O%,
for symptomatic parasitemia efficacy was 9%, statistical
power 95% probability of efficacy ~50%). SPf66 was
reported to be 31% effective (95% conficence interval
O-52%), with blood slides made only if temperature was
37.5”, in Tanzania6’, also statistically consistent with the
present study (for asymptomatic parasitemia efficacy
was O%, for symptomatic parasitemia efficacy was 9%,
statistical power 95% probability of efficacy ~50%). In
the present study, visits to ascertain symptoms were
made every day rather than waiting for patients to
present, and blood slides were made every 1 week rather
than every 4-8 weeks, and with such frequent active
seeking the observation remains that every volunteer of
both vaccine and control groups had a parastiemia at
least once, and both vaccine and control groups had
similar incidences of symptomatic parasitemia.
The SPf66 vaccine was tested in the Gambia and
found to have a protective efficacy of 8% (95% confidence interval - 18%29%, P=0.50)62, in statistical
agreement with the present study showing protective
efficacy against symptomatic parasitemia of 9% (statistical power 95% probability of efficacy <50%), and also in
statistical agreement with the study in Tanzania showing
protective efficacy of 31% (95% conficence interval
O-52%)61.
With R32LR, in an immunigenicity study in semiimmune volunteers, with vaccination at 0, 8 and 16
weeks, in Thailand, anti-circumsporozoite
antibodies
rose significantly, but fe1163.Minimal rainfall precluded
natural malaria challenge, leaving the question of
vaccine efficacy unresolved in that study62.
Newer candidate vaccines may induce both humoral
and cellular immunity, with better adjuvants, presentation and delivery of antigens against multiple parasite
stages.
This present study in malaria-endemic semi-immune
volunteers was useful for comparison with studies in
animals and non-immune volunteers, in the absence of
definitive laboratory assays of protective immunity. It
showed that high levels of anti-circumsporozoite
repeat
antibody, induced by this antigen, with this adjuvant,
were ineffective in preventing malaria in this endemic
population, exposed to a range of intensity of natural
challenge.
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